The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

@article{Berman2007TheEA,
  title={The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.},
  author={Robert M. Berman and Ronald N. Marcus and Ren{\'e} Swanink and Robert D. McQuade and William H. Carson and Patricia K. Corey-Lisle and Arif Khan},
  journal={The Journal of clinical psychiatry},
  year={2007},
  volume={68 6},
  pages={843-53}
}
OBJECTIVE To assess the efficacy and safety of aripiprazole versus placebo as adjunctive treatment to standard antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who showed an incomplete response to 1 prospective and 1 to 3 historical courses of ADT within the current episode. METHOD The study comprised a 7- to 28-day screening phase, an 8-week prospective treatment phase, and a 6-week double-blind treatment phase. Patients with DSM-IV-TR-defined MDD were enrolled… CONTINUE READING